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Abstract
Numerous genetic factors that influence breast cancer risk are known.However, approximately two-thirds of the overall familial
risk remain unexplained. To determine whether some of the missing heritability is due to rare variants conferring high to
moderate risk, we tested for an association between the c.5791C>T nonsense mutation (p.Arg1931*; rs144567652) in exon 22 of
FANCM gene and breast cancer. An analysis of genotyping data from 8635 familial breast cancer cases and 6625 controls from
different countries yielded an association between the c.5791C>T mutation and breast cancer risk [odds ratio (OR) = 3.93 (95%
confidence interval (CI) = 1.28–12.11; P = 0.017)]. Moreover, we performed two meta-analyses of studies from countries with
carriers in both cases and controls and of all available data. These analyses showed breast cancer associations with OR = 3.67
(95% CI = 1.04–12.87; P = 0.043) and OR = 3.33 (95% CI = 1.09–13.62; P = 0.032), respectively. Based on information theory-based
prediction, we established that themutation caused an out-of-frame deletion of exon 22, due to the creation of a binding site for
the pre-mRNA processing protein hnRNP A1. Furthermore, genetic complementation analyses showed that the mutation
influenced the DNA repair activity of the FANCM protein. In summary, we provide evidence for the first time showing that the
common p.Arg1931* loss-of-function variant in FANCM is a risk factor for familial breast cancer.
Introduction
Breast cancer (OMIM #114480) is a common oncological disease
that accounts for 23% of all malignancies in women and is esti-
mated to cause 1 400 000 new cases andmore than 450 000 deaths
worldwide every year (1). It has been estimated that ∼13% of all
breast cancer cases have one or more affected relatives and
that risks of breast cancer increase with greater numbers of af-
fected relatives (2). This increased risk is also due to known
germ-line susceptibility alleles including rare, high-risk loss-of-
function variants predominantly found in BRCA1 and BRCA2 (3).
In addition, 94 common single nucleotide polymorphisms
(SNPs) have been identified that individually confer only a slightly
increased risk of breast cancer, but combined in a multiplicative
model account for ∼16% of familial breast cancer risk (4).
BRCA1 and BRCA2 gene products contribute to cell homeosta-
sis through the DNA damage response mediated by homologous
recombination. Moreover, mutations in BRCA2 (also known as
FANCD1) have been shown to cause Fanconi Anaemia (FA), a
rare recessive disorder characterized by genomic instability, pro-
gressive bonemarrow failure and predisposition to cancer. These
genes encode proteins belonging to the FA pathway, which be-
comes activated in response to breaks in single- and double-
stranded DNA. Monoallelic variants in several of these genes,
includingATM, PALB2/FANCN and RAD51C/FANCO, have been de-
tected in non-BRCA1 and BRCA2 familial breast cancer cases, but
at a lower frequency in controls, consistent with moderate to
high risks of breast cancer (5–7). The rare variants identified in
these genes have a cumulative frequency in familial cases of
0.5–2%. However, with the exception of a few recurrent or founder
mutations in specific populations, each of these mutations is
generally very rarewithmany reported in single families. In con-
trast, few rare truncating and pathogenicmissense variants have
been found in CHEK2 (8), with much of the risk attributed to this
gene explained by the single moderate-penetrance founder
allele, c.1100delC (9).
Recent studies have underlined the challenges in identifying
new breast cancer predisposition genes. Exome sequencing in
families followed by gene re-sequencing in additional cases
and controls have provided conflicting results for XRCC2 (10,11),
and inconclusive results for FANCC and BLM (12), raising ques-
tions about the statistical power of these studies (13). Similarly,
the evidence that SLX4, an FA gene, is associated with breast can-
cer risk is limited, given that the analysis of large numbers of
familial cases identified only three inactivating variants (14–16).
Screening for risk-associated mutations in BRCA1 and BRCA2
is commonly used in clinical practice to identify at-risk indi-
viduals and to direct them towards specific surveillance
programmes or risk reduction options. By including additional
breast cancer predisposition genes in gene panels analysed
by next-generation sequencing, risk prediction can be performed
in a larger fraction of individuals at a reduced cost with
rapid turnaround time. With the goal of identifying new risk-
associated genes, we and others previously performed exome se-
quencing in multiple-case breast cancer families (17). One of the
findings of that study was a single proband heterozygous for the
c.5791C>T variant (rs144567652) in FANCM, another gene in-
volved in the FA pathway. The variant was predicted to introduce
a stop codon (TGA) in exon 22, causing the loss of 118 amino acids
from the C-terminus (p.Arg1931*). A subsequent case–control
study detected the mutation in 10 of 3409 (0.29%) familial cases
without known mutations in BRCA1 and BRCA2 and in 5 of 3896
(0.13%) controls from different national studies. The estimated
odds ratio (OR) was 2.29 [95% confidence interval (CI) = 0.71–
8.54; P = 0.13]. In an effort to establish the significance of this
estimate (17), a further analysis in a larger cohort was performed.
Results
Association with breast cancer risk
We investigated the c.5791C>Tmutation in a large series of famil-
ial cases without knownmutations in BRCA1 and BRCA2 and in a
comparable set of control individuals from Italy, France, Spain,
Germany, Australia, USA, Sweden and TheNetherlands. Themu-
tationwas found in 18 of 8635 (0.21%) cases (pedigrees are shown
in Supplementary Material, Fig. S1) and in 4 of 6625 (0.06%) con-
trols (Table 1) giving a statistically significant association with
breast cancer risk with an age-adjusted OR of 3.93 (95% CI =
1.28–12.11; P = 0.017). The c.5791C>T mutation is rare and we
observed a large variation in allele frequency in cases and con-
trols across studies. To control for population stratification, we
performed a meta-analysis, including only studies in which mu-
tation carriers were detected in both cases and controls (Italy,
France and Australia). Starting from the ORs and their 95% CIs
obtained from a univariate logistic model within each country,
we obtained a pooled OR = 3.67 (95% CI = 1.04–12.87; P = 0.043)
(Table 2). A second meta-analysis was performed by exploiting
all the available data. We implemented an exact conditional lo-
gistic regressionmodel including ‘country’ as a random covariate
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in order to control for population stratification and for the ab-
sence of variant carriers in some countries (Sweden and USA)
[OR = 3.330 (95% CI = 1.087–13.615; P = 0.0320)].
Expression of the mutant allele
To verify the functional consequences of the c.5791C>T muta-
tion, we first performed reverse transcriptase-polymerase chain
reaction (RT-PCR) in lymphoblastoid cell lines (LCLs) derived
from two mutation carriers. Amplifying a product spanning
exons 22 and 23, sequence analyses revealed very low levels of
the mutated transcript compared with corresponding normal
mRNA. Treatment with a protein synthesis inhibitor, cyclohexi-
mide, did not alter mutant transcript levels (Fig. 1), suggesting
that the effect was probably not related to nonsense-mediated
decay (NMD), but rather to a defect in mRNA splicing itself.
Effect on the mRNA splicing
The occurrence of exonic mutations affecting pre-mRNA splicing
is well documented inmany human disease genes (18). These in-
clude nonsense mutations, a phenomenon referred to by some
authors as ‘nonsense-associated altered splicing’ (19). Therefore,
to assess the impact of c.5791C>T on splicing regulatory binding
sites controlling exon definition, we performed information the-
ory-based mutation analysis, using the Automated Splice Site
and Exon Definition Analysis (ASSEDA) server (20). The variant
was predicted to create a strong binding site [information content
(Ri) = 4.6 bits] for the splicing factor hnRNP A1 at position
c.5790_5795 (Fig. 2A) (21). Exon definition analysis suggested
that the creation of this site would completely suppress exon
recognition (Ri,total from 3.5 to −2.5 bits), predicted to result in
exon skipping. This was confirmed by RT-PCR, using forward
and reverse primers in exons 21 and 23 which detected two
amplification products (Fig. 2B). The upper band derived from
the full-length transcript (Supplementary Material, Fig. S2),
whereas the lower band derived from an aberrant transcript lack-
ing the entire exon 22 (c.5717_6008del292) (Fig. 2C). This exon
skipping is predicted to encode a protein that incorporates
11 additional residues and to lead to a premature termination
of translation that results in the loss of 132 amino acids from
the FANCM C-terminus (p.Gly1906Alafs12*).
Skipping of exon 22 is mediated by hnRNP A1
A pull-down experiment with HeLa cell extracts followed by
western blot analysis showed that the hnRNPA1 protein specific-
ally bound to RNA oligonucleotides spanning FANCM position
r.5779_5804 and carrying the r.5791C>U mutation, whereas a
very weak interaction was observed with the corresponding nor-
mal oligonucleotide (Fig. 2D). These results are in agreementwith
the outcomes of the in silico analyses and provide evidence that
the mechanism through which the c.5791C>T mutation causes
exon 22 skipping ismediated by the binding of hnRNPA1 protein.
DNA repair activity-based functional studies
We then checked whether the c.5791C>T mutation (Δ22) affects
FANCM activity in DNA repair, by genetic complementation of
the following FA-associated cell phenotypes: hypersensitivity
to mitomycin C (MMC)- and diepoxybutane (DEB)-induced
chromosome fragility. As an internal control, we used a previously
described nonsense mutation (p.S724X; rs137852864) (22) that
leads to a premature stop codon (stop). Mutant cDNAs were
Table 1. Number and frequency of mutation carriers and non-carriers in cases and controls
Geographical group Country Cases Controls
Carriers Non-carriers Freq% Carriers Non-carriers Freq%
South/Western Europe Italy 6 2209 0.27 1 1483 0.07
France 5 1570 0.32 1 1323 0.08
Spain 3 751 0.40 0 286 NA
All 14 4530 0.31 2 3092 0.06
Non-South/Western Europe Germany 0 1636 NA 1 1899 0.05
Australia 3 1235 0.24 1 1164 0.09
USA 0 517 NA 0 322 NA
Sweden 0 484 NA 0 0 NA
The Netherlands 1 215 0.46 0 144 NA
All 4 4087 0.10 2 3529 0.06
All populations Total 18 8617 0.21 4 6621 0.06
NA, not applicable.
Table 2. Meta-analysis of the study results from countries with mutation carriers in both cases and controls
Country Cases Controls OR 95% CI P-value
Carriers Non-carriers Freq% Carriers Non-carriers Freq%
Italy 6 2209 0.27 1 1483 0.07 4.03 0.48−33.47 0.197
France 5 1570 0.32 1 1323 0.08 4.21 0.49−36.10 0.189
Australia 3 1235 0.24 1 1164 0.09 2.82 0.24−27.13 0.369
Pooled 14 5014 0.28 3 3970 0.08 3.67 1.04−12.87 0.043
OR, odds ratio; CI, confidence interval.
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generated by site-directedmutagenesis and cloned into lentiviral
vectors to stably transduce Fancm−/− immortalized mouse em-
bryonic fibroblast (MEFs).Wild-type, Δ22 and stop alleleswere ex-
pressed at similar levels in infected cells (Supplementary
Material, Fig. S3). As expected,wt FANCMbut not the prematurely
truncated forms rescued MMC hypersensitivity of Fancm−/−MEFs
(Fig. 3A). Similar results were observed in a chromosome fragility
Figure 1. Sequencing analysis of the FANCM gene and transcript. (A) Genomic
DNA fragment PCR amplified using both primers in exon 22 from an LCL
carrying the c.5791C>T mutation. (B) cDNA fragment amplified by PCR using a
forward primer in exon 22 and a reverse primer in exon 23. A strong reduction
in the expression of the mutant allele was observed in both cycloheximide
treated and untreated cells. cDNA from a non-carrier individual was used as a
control. The position of the mutation is indicated by the arrows. Identical
results were observed in an additional mutated LCL.
Figure 2. Analysis of the effect of the FANCM c.5791C>T mutation on RNA. (A)
Sequence logo of hnRNP A1 binding sites generated as described in Materials
and Methods. The opal codon (TGA, boxed) introduced by the FANCM c.5791C>T
mutation (in bold red) is contained at positions 1–3 of the hnRNP A1 binding-site
encompassing nucleotides c.5790_5795. The hnRNP A1 binding-site strength
computed by the ASSEDA software for the normal and mutated sequences is
reported. (B) Agarose gel electrophoresis of the RT-PCR products using a
forward primer in exon 21 and a reverse primer in exon 23. M, molecular
marker (ΦX-174 HaeIII digested); 1, no template as a negative control for PCR; 2,
genomic DNA as a negative control for the specificity of cDNA amplification; 3
and 4, cDNAs from LCLs carrying the c.5791C>T mutation; 5–14, cDNAs from
LCLs derived from 10 mutation negative individuals, used as reference controls.
The sizes of the full-length (FL) and Δexon22 (Δ22) transcripts are indicated. (C)
Sequence of the aberrant band excised from the gel showing the skipping of the
entire exon 22. (D) Western blot analysis of biotin RNA–hnRNP A1 protein pull
down using a goat polyclonal antibody. The sequence of the used RNA
oligonucleotides encompassing FANCM positions r.5779_5804 is reported, with
the r.5791C>U mutation in bold red, the opal codon enlightened in light grey
and the predicted hnRNP A1 binding site created by the mutation boxed in red.
As a control for the pull-down efficiency and specificity, we used an antibody
against the ELAVL1/HuR protein for which a binding site, boxed in green, is
predicted in both RNA oligonucleotides. Input, 10% of total HeLa cell line extract
used in the pull-down assay. No, no RNA used as a negative control; 1, normal
RNA; 2, RNA carrying the r.5791C>U mutation. The results shown here are
representative of two independent experiments.
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assay (Fig. 3B). These observations lead to the conclusion that the
Δ22 form of FANCM is deficient in DNA repair of MMC- and DEB-
induced stalled replication forks.
Discussion
Genotyping of the c.5791C>T variant from FANCM in 8635 familial
cases with no mutations in BRCA1 and BRCA2 and in 6625 con-
trol individuals from Italy, France, Spain, Germany, Australia,
USA, Sweden and The Netherlands indicate that the variant is
associated with risk of breast cancer with OR of 3.93. The asso-
ciation between the variant and breast cancer risk is reinforced if
the data from the present case–control analysis are combined
with those of Gracia-Aznarez et al. (17). Overall, the variant was
detected in 28 of 12 044 (0.23%) familial cases and 9 of 10 521
(0.09%) controls, corresponding to a naive OR, adjusted for the
‘study’ covariate, of 2.83 (95% CI = 1.33–6.01; P = 0.007). It has to
be noted that these studies were based on cases with positive
family history for breast cancer and/or disease early onset.
These selected cases are likely to be enriched in predisposing
genetic factors. Consequently, the ORs observed here could be
higher than those expected in unselected cases and population
controls.
Population stratification may occur when a rare mutation is
tested in individuals from different countries. We took into con-
sideration this critical issue by performing two meta-analyses.
The first was based only on studies with carriers in both cases
and controls, whereas the second exploited all the individual
data. Both analyses supported the c.5791C>T mutation as a
breast cancer risk factor (OR = 3.67 and 3.33, respectively), al-
though with borderline statistical significance. However, these
analyses do not completely guard against stratification effect.
Hence, these results need to be taken with caution. In this light,
genotyping of additional variants in much larger series of unse-
lected breast cancer cases andmatched controlswill be needed to
confirm FANCM as a breast cancer susceptibility gene.
The functional characterization of the mRNA transcript de-
rived from the c.5791C>T allele shows that the variant causes
the skipping of exon 22 introducing a premature stop codon. In
addition, genetic complementation assays revealed the mutated
protein lacks DNA repair activity. These results support that the
FANCM c.5791C>T mutation is pathogenic. Of note, our observa-
tions at the mRNA level emphasize the notion that, although
nonsense mutations are usually considered as inherently dele-
terious, transcript analyses are required for a precise assessment
of actual functional consequences.
Interestingly, while this article was in preparation, another
FANCM C-terminus truncating mutation, the c.5101C>T (p.
Q1701*), was detected by the exome sequencing of 11 Finnish
breast cancer families (23). The c.5101C>T mutation was shown
to be significantly more frequent in Finnish breast cancer cases
compared with controls (OR = 1.86; 95% CI = 1.26–2.75; P = 0.0018),
to have higher effect in cases with family history (OR = 2.11; 95%
CI = 1.34–3.32; P = 0.0012)—although incomplete co-segregation
with the disease was observed among most of the families—
and with the stronger effect (OR = 3.56; 95% CI = 1.81–6.98;
P = 0.0002) inmutation carriers affectedwith triple-negative (oes-
trogen receptor-, progesterone receptor- and HER2-negative)
breast cancer (TNBC). In addition, the age at breast cancer diagno-
sis was not different between variant carriers and non-carriers
and the variant allele was not subjected to mRNA NMD (23).
Among the cases we studied, there were no significant differ-
ences in age at breast cancer diagnosis in the 18 variant carriers
versus the non-carriers (data not shown). Moreover, because
variant carriers with TNBC were not found, it was not possible
to associate the c.5791C>T mutation with this specific tumour
subtype (see Supplementary Material, Table S1). Our data, to-
gether with the observations by Kiiski et al., support the notion
that loss-of-function mutations of FANCM are moderate breast
cancer risk factors. Additional studies, such asmodified segrega-
tion-analysis in families, are warranted to provide age-specific
risk estimates for FANCM mutation carriers.
The 1100delC allele of CHEK2 has a number of properties simi-
lar to c.5791C>T in FANCM. This allele has been shown to be as-
sociated with moderate risk and has been found in many
countrieswith a frequency that is higher inNorth-Eastern Europe
and decreases in Southern Europe (9). Taking into consideration
the geographic origin of the individuals included in our study, we
observed that the frequency of the mutation carriers in South-
Western European countries (16/7638 = 0.21%) was higher, al-
though with borderline statistical significance (Fisher’s exact
test, P = 0.052), than that observed in all other countries
Figure 3. Functional studies of the FANCM mutation. (A) Analysis of cellular MMC sensitivity. MEFs expressing Δ22-FANCM allele (Fancm−/− + Δ22 FANCM) are more
sensitive to MMC than the cell expressing the wt FANCM allele (Fancm−/− +wt FANCM). Not transduced MEFs (MEF Fancm−/−) and MEF Fancm−/− expressing a FANCM
with loss-of-function mutation p.S724X (Fancm −/− + stop FANCM) are used as controls (N = 3; error = standard deviation). (B) Chromosome fragility induced by DEB
treatment. Fancm−/− + Δ22 FANCM and Fancm−/− + stop FANCM cells show higher chromosome fragility than Fancm−/− + wt FANCM. Twenty metaphases were
analysed for chromosome breaks. Results are represented as mean number of breaks per cells and the error bars are SEM.
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evaluated (6/7622 = 0.08%) (Table 1). This suggests that this
FANCM mutation has a frequency gradient that is opposite of
that reported for the CHEK2 1100delC. Nevertheless, the relatively
small numbers of carriers observed suggest that further analyses
in specific populations would be worthwhile. For example, data
from the Exome Aggregation Consortium (ExAC), Cambridge,
MA (http://exac.broadinstitute.org) (March 2015, accessed), that
is collecting exome sequencing data from individuals included
in various disease-specific and population genetic studies, indi-
cate that c.5791C>T occurs in the Finnish population with a car-
rier frequency of nearly 1%.
The FA pathway is generally subdivided into upstream pro-
teins, assembling into the ‘core complex’ and ‘downstream ef-
fectors’. The ‘core complex’ ubiquitinates the FANCI–FANCD2
complex and this activates the pathway coordinating the action
of the downstream effectors. The latter include FANCD1/BRCA2,
FANCN/PALB2, FANCJ/BRIP1 and FANCO/RAD51C that are re-
quired for DNA repair by homologous recombination and are
all breast cancer genes (24). This has suggested that the in-
volvement of FA genes in breast cancer susceptibility could
be limited to the FA downstream effectors (24,25). The
FANCM protein has different functional domains, including a
DEAH translocase domain at the N-terminus, and domains
for interaction with proteins mediating DNA binding between
amino acids 675 and 790 for interaction with MHF1 and MHF2,
and at the C-terminus beyond amino acid 1799, for interaction
with FAAP24 (26). Moreover, FANCM–FAAP24–MHF1–MHF2 acts
as an independent ‘anchor complex’ that recognizes the dam-
age caused by interstrand cross-linking agents and recruits the
FA core complex (26). Furthermore, FANCM is not essential
for complete ubiquitination of the FANCI–FANCD2 complex
(24,26). Finally, the FANCM/MHF complex has a translocase ac-
tivity that is independent of the core complex proteins (27).
Hence, FANCM has a direct activity in maintaining the DNA in-
tegrity that can be independent of the FA pathway. In this
light, it is possible that the increased risk for breast cancer
conferred by the c.5791C>T variant is due to a direct impair-
ment of the DNA damage response as for the FA downstream
effectors.
BRCA1 and BRCA2 are established breast cancer risk factors
with high penetrance and PALB2was also recently shown to con-
fer a high breast cancer risk (28). Although these three genes en-
code for downstream effectors of the FA pathway, their proteins
are also involved in other DNAdamage responses, including dou-
ble-strand break repair. Thus, BRCA1, BRCA2 and PALB2 exert
DNA damage response functions that one can speculate to be
of greater magnitude than FANCM. Consequently, susceptibil-
ity to breast cancer is expected to be higher in BRCA1, BRCA2
or PALB2mutation carriers and lower in carriers of FANCMmu-
tations, which is in agreement with our data on the c.5791C>T
mutation and similar data on the c.5101C>T mutation (23).
By analogy, the abrogation of BRCA1, BRCA2 and PALB2 func-
tions on the one hand, and the abrogation of FANCM function
on the other, seem to impact FA differentially. It is known
that biallelic BRCA2 and PALB2mutations cause FA, and recent-
ly, initial evidence of the involvement of BRCA1 mutations in
the disease have been documented. BRCA1 biallelic mutations
were found in a woman showing anomalies consistent with a
FA-like disorder, which supports BRCA1/FANCS as a novel FA
gene (29). In contrast, the role of FANCM in FA is questionable.
The only FA patient reported so far with truncating FANCMmu-
tations also carried deleterious mutations in FANCA (22,30).
Moreover, individuals homozygous for the truncating FANCM
mutations c.5101C>T and c.5791C>T did not present with FA
(31) indicating that, at present, FANCM cannot be considered
to cause FA.
In conclusion, based on the analysis of large sets of cases and
controls and functional observations, our study provides evi-
dence that the FANCM c.5791C>T is a novel risk factor for familial
breast cancer.
Materials and Methods
Study populations
Twenty-five case–control cohorts were included in the study
through a collaboration call circulated among the COMPLEXO
participants (32). Centre or study details, number and description
of cases and controls are reported in Supplementary Material,
Table S2. The cases included in this study were (i) affected with
breast cancer at age ≥18, (ii) eligible to BRCA1- and BRCA2-muta-
tion testing based on breast and/or ovarian cancer family history
(at least one first- or second-degree female relatives with either
tumours), or because affected with early onset (≤40 years) or bi-
lateral (≤50 years) breast cancer and (iii) negative to BRCA1- and
BRCA2-mutation test. A few of the centres or studies contributing
to this article used slightly different inclusion criteria, and these
are described in Supplementary Material, Table S2. In all cohorts,
cases and controls were female Caucasians recruited in the same
area.All individuals included in the studysigned an informedcon-
sent to the use of their biological samples for research purposes.
The participation to this study was approved by ethical commit-
tees or review boards of the participant centres or studies.
Mutation genotyping
Details of genotype analyses for FANCM (NG_007417.1,
NM_020937.2) c.5791C>T mutations are reported in Supplemen-
tary Material, Table S2. For most studies, cases and controls
were genotyped at coordinating centre (IFOM, Milano) by custom
TaqMan SNP genotyping assay (Life Technologies) using the
following primers and probes. Forward primer: 5′-AGCCTGCT
GACTACCTTAATTGG-3′; reverse primer: 5′-CTTTAGCAAATC
TGCGGTTTCTTCT-3′; probe 1: 5′-TGAAAAGAATTCGGATTCC-3′;
probe 2: 5′-TGAAAAGAATTCAGATTCC-3′. In every 96-well plate,
at least one positive control and two blank controls were in-
cluded. The remaining samples were genotyped at local centres
using TaqMan assay or high-resolutionmelting. All positive sam-
ples were confirmed by double-strand Sanger sequencing. Two
studies (SWE-BRCA and MAYO) provided genotyping data from
previous next-generation sequencing studies.
Statistical analyses
Logistic regression analysis was used to test the association be-
tween mutation frequencies and risk of breast cancer (33). Age
was included in the model as adjustment covariate and the
adjusted ORs and its 95% CIs were estimated. A meta-analysis
considering only countries in which mutation carriers were
observed in both cases and controls was performed based
on mixed models (34) starting from single-study estimates. A
meta-analyses exploiting all individual data was performed
using an exact conditional logistic regression model (35).
The statistical analyses were performed with the SAS software
(Version 9.2; SAS Institute Inc., Cary, NC).
Information theory-based mutation analyses
The ASSEDA server (http://mutationforecaster.com) has been
developed to predict the molecular phenotype of putative
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splicing mutations (20) and implemented to take into account
their effect on splicing factor binding sites. In particular, CLIP-seq
libraries for hnRNPA1 (36) were used to derive information theory-
based position weight matrix (PWM), depicted in Figure 2A.
PoWeMaGen software, which uses Bipad (37) to generate min-
imum entropy alignments, generates a series of potential bind-
ing-site models over a range of input parameters. To mitigate
against phasing the alignment on natural splice sites instead of
adjacent hnRNP A1 binding sites, models were built from shorter
sequences, ranging in lengths between 18 and 25nucleotides (nt).
The optimal model was determined by maximizing incremental
information by varying binding-site length (6–10 nt), number of
Monte Carlo cycles (250–5000) and allowing either zero or only
one site per sequence (OOPS). The model with the highest aver-
age information used a maximum fragment length of 18 nt,
1000 Monte Carlo cycles, OOPS and a single-block binding-site
length of 6 nt. This sequence is frequently present in sites
cross-linked to hnRNP A1 protein (34). Of the 140 431 hnRNP A1
binding sites used to create the information theory-based
model, the wild-type sequence, CCGAAT, is not represented,
and the mutant site, CTGAAT, occurred 716 times. The model
was validated with known hnRNP A1 binding sites and splicing
affecting mutations (38–41). The effects of mutations at hnRNP
A1 sites on exon definition were determined from the total infor-
mation content (Ri,total), by incorporating changes in the
strengths of these sites, corrected for the gap surprisal, which re-
presents the distance between the hnRNPA1 site and the natural
splice site. Gap surprisal valueswere determined by scanning the
genome for hnRNPA1 sites with the PWM, and then determining
the frequency of each interval length between known natural
sites and the nearest hnRNP A1 site, separately for exons and in-
trons. Differences between the natural and mutated exon Ri,total
values correspond to changes in the abundance of the respective
isoforms and can predict exon skipping. The calculation is car-
ried out by the ASSEDA server (20). Exon definition analysis was
validated for a set ofmutations that affect hnRNPA1 binding-site
strength (39,40).
Cell lines
Epstein–Barr virus-immortalized human LCLs were established
from peripheral blood derived from 2 carriers of the c.5791C>T
mutation and 10 normal controls (42). LCLs were maintained in
RPMI 1640 medium supplemented with 15% foetal bovine
serum plus 1% penicillin–streptomycin. The HeLa cell line was
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mentedwith 10% foetal calf serumplus 1% penicillin–streptomy-
cin at 37°C in a humidified 5% CO2 atmosphere. The HeLa cell line
was authenticated by short tandem repeat analysis using the kit
GenePrint10 kit (Promega). Fancm−/− immortalizedMEFs (43)were
a kind gift of Dr H. Te Riele from The Netherlands Cancer Insti-
tute, Amsterdam. MEFs were cultured in DMEM 10% fetal calf
serum supplemented with antibiotics. All the cell lines used in
this study were routinely checked for mycoplasma contamin-
ation using the PCR Mycoplasma Detection Set (Takara) or the
MycoAlert™ Mycoplasma Detection Kit (Lonza).
Transcript analyses
Potential degradation of unstable transcripts containing prema-
ture termination codons via nonsense-mediated mRNA decay
(NMD) was prevented by growing LCLs in the presence of cyclo-
heximide (100 µg/ml) for 4 h. Total RNA was purified from LCLs
using the Nucleospin RNA II (Macherey-Nagel) and the cDNA
was synthesized using random primer and Maxima H Minus En-
zyme (Thermo Scientific), according to themanufacturers’ proto-
cols. cDNAs were PCR amplified using the following primers.
Exon 21, forward: 5′-CAAGTTCATTGAGCAGATCCAG-3′; exon 22,
forward: 5′-ACATCAAGGATGTTTAGGA-3′; exon 22, reverse: 5′-
GTGCCTCACTTTTATTACTA-3′; exon 23, reverse: 5′-CCCATCTT
GAGCAGCTTGA-3′. Amplification products were visualized on
agarose gel stained with ethidium bromide and directly charac-
terized by Sanger sequencing. Alternatively, single PCR frag-
ments were excised from the gel, purified using the Wizard®
SW Gel and PCR Clean-Up System (Promega) and sequenced.
Biotin RNA–protein pull-down assay
Protein extraction was performed starting from ∼5 × 106 HeLa
cells. These cells were harvested by centrifugation at 4°C for
5 min, washed twice with 1× phosphate buffered saline (PBS)
and lysed in lysis buffer [25 m Tris (pH 7.4), 150 m NaCl,
1 m ethylenediaminetetraacetic acid, 1% Nonidet P-40, 5% gly-
cerol] containing protease inhibitor (Sigma–Aldrich), on ice for
30 min. Following centrifugation, the protein concentration was
determined by Bradford assay (Bio-Rad). Mutated and normal
RNA oligonucleotides were biotinylated at the 3′ end using the
RNA 3′ End Desthiobiotinylation Kit (Thermo Scientific Pierce),
according to the manufacturer’s instructions. For each binding
reaction, 50 pmol of biotinylated RNA oligonucleotides were
coupled to 50 μl of StreptavidinMagnetic Beads (Thermo Scientif-
ic Pierce) and incubated with an equal amount of HeLa cell ly-
sates in 1× protein–RNA binding buffer [0.2 M Tris (pH 7.5),
0.5 M NaCl, 20 m MgCl2, 1% Tween-20 detergent], for 2 h at 4°C
with agitation. The bound proteinswere eluted from themagnetic
beads by incubating with 50 μl of biotin elution buffer (Thermo
Scientific Pierce) for 30 min at 37°Cwith agitation. The eluted pro-
teins were subjected to 4–15% sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis gradient gel and visualized by
western blotting using a goat polyclonal antibody against
hnRNP-A1 (#sc-10029, Santa Cruz Biotechnology) or a mouse
monoclonal antibody against ELAVL1/HuR (#1862775, Thermo
Scientific Pierce). The binding site for the ELAVL1/HuR protein
was identified with ASSEDA (http://splice.uwo.ca/logos.html).
Plasmids used for functional studies
The doxycycline-inducible lentiviral vector pLVX-TRE3G-FANCM
was kindly provided by Dr N. Ameziane (Vrije Universiteit
Medical Center, Amsterdam, The Netherlands) and mutated
by site-directed mutagenesis with the QuickChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies), as previously
described (42) and using the following PAGE purified mutagenic
primers. Δ22 primer 1: 5′-GAAAAGGACAGAGAAAAAACAGCT
CACTTCAAGAAATCTCCATG-3′, Δ22 primer 2: 5′-CATGGAGATT
TCTTGAAGTGAGCTGTTTTTTCTCTGTCCTTTTC-3′, c.2171C>A
primer 1: 5′-TGAGGAAAACAAACCAGCTCAAGAATAAACCACTG
GAATTC-3′ and c.2171C>A primer 2: 5′-GAATTCCAGTGGTT
TATTCTTGAGCTGGTTTGTTTTCCTCA-3′. The sequences of all
FANCM constructs were verified by Sanger sequencing to confirm
that they only bore the intended mutations.
Lentiviral particles production and cell transduction
To prepare lentiviral particles, 5 × 106 HEK-293 T cells were plated
into 10 cm dishes. The next day, medium was changed with a
fresh one containing 30 µ Chloroquine (Sigma) and cells were
transfected with the lentiviral expression vectors and the helper
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plasmids (PAXand ENV) using theCalPhosMammalianTransfec-
tion Kit (Clontech). Themediumwas changed 24 h after transfec-
tion, and 24 h later, the lentivirus-containing supernatant was
collected and filtered through a 0.45 µm filter (Millipore). Add-
itional supernatant was collected after additional 24 h, filtered
and pooled with the initial one. Pooled supernatants were centri-
fuged in a Beckman JS-24.38 rotor at 19 500 rpm for 1.5 h at 4°C.
Pellets were resuspended in PBS (50 µl of PBS/10 ml of super-
natant) and stored at −80°C. Sixty thousands of Fancm−/− MEFs
per well were seeded in a 12-well plate. After 24 h, cells were in-
fectedwith 20 µl of concentrated viral supernatant in the presence
of 1 µg/ml polybrene (Millipore). Twenty-four hours later, infected
cells were selectedwith puromycin (2.5 µg/ml). Transgene expres-
sions were checked by real-time PCR.
MMC sensitivity test
Twenty-five thousand cells of each cell line were seeded in 2 ml
of complete medium supplemented with 2 µg/ml doxycycline
in 12 wells of 6-well plates. The next day, MMC was added at
the indicated doses and the cell sensitivity was evaluated 72 h
after cell cultures were washed with PBS. Cells were collected in
a volume of 300 µl of trypsin and 700 µl of complete medium
and counted with a Z2™ coulter counter (Beckman Coulter) (44).
Chromosome fragility test
Two hundred thousand cells were seeded in complete medium
supplemented with 2 µg/ml doxycycline. Twenty-four hours
later, DEB was added at the indicated concentrations, and meta-
phase spreads were then harvested 3 days later as it follows. Col-
cemid™ (Sigma) was added at 0.1 µg/ml final concentration and
after 2 h, cells were trypsinized, washed in PBS, the pellet was re-
suspended in hypotonic solution (0.075 M KCl) and incubated for
25 min at 37°C. Cells were then washed three times with metha-
nol:acetic acid (4:1) and the cell suspension was dropped on
microscope slides and Giemsa stained. Twenty metaphase cells
from each DEB concentration were scored for chromosome
breakage after image capture using the Metafer Slide Scanning
Platform from Metasystems (45).
Supplementary Material
Supplementary Material is available at HMG online.
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